170 related articles for article (PubMed ID: 28100395)
1. Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Mantis C; Kandela I; Aird F;
Elife; 2017 Jan; 6():. PubMed ID: 28100395
[TBL] [Abstract][Full Text] [Related]
2. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Kandela I; Chou J; Chow K;
Elife; 2015 May; 4():. PubMed ID: 27879198
[TBL] [Abstract][Full Text] [Related]
3. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Kandela I; Chou J; Chow K; ;
Elife; 2015 May; 4():. PubMed ID: 25998055
[TBL] [Abstract][Full Text] [Related]
4. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
5. Tumor-penetrating Peptide-integrated Thermally Sensitive Liposomal Doxorubicin Enhances Efficacy of Radiofrequency Ablation in Liver Tumors.
Yan F; Wang S; Yang W; Goldberg SN; Wu H; Duan WL; Deng ZT; Han HB; Zheng HR
Radiology; 2017 Nov; 285(2):462-471. PubMed ID: 28631963
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma.
Deng C; Zhang Q; Fu Y; Sun X; Gong T; Zhang Z
ACS Appl Mater Interfaces; 2017 Jan; 9(2):1280-1292. PubMed ID: 28009503
[TBL] [Abstract][Full Text] [Related]
7. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolization (TACE) with iRGD peptide in rabbit VX2 liver tumor.
Liu X; Xie Y; Qi X; Xu K
J Cancer Res Ther; 2020; 16(7):1703-1709. PubMed ID: 33565520
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Greenwald DR; Ruoslahti E
Science; 2010 May; 328(5981):1031-5. PubMed ID: 20378772
[TBL] [Abstract][Full Text] [Related]
11. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
12. Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data.
Kandela I; Aird F;
Elife; 2017 Jan; 6():. PubMed ID: 28100397
[TBL] [Abstract][Full Text] [Related]
13. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Aird F; Kandela I; Mantis C;
Elife; 2017 Jan; 6():. PubMed ID: 28100400
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
Deng Z; Xiao Y; Pan M; Li F; Duan W; Meng L; Liu X; Yan F; Zheng H
J Control Release; 2016 Dec; 243():333-341. PubMed ID: 27984104
[TBL] [Abstract][Full Text] [Related]
15. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
[TBL] [Abstract][Full Text] [Related]
16. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.
Accardo A; Salsano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Tesauro D; Aloj L; De Rosa G; Morelli G
Int J Nanomedicine; 2012; 7():2007-17. PubMed ID: 22619538
[TBL] [Abstract][Full Text] [Related]
17. Protective and anticancer effects of orange peel extract and naringin in doxorubicin treated esophageal cancer stem cell xenograft tumor mouse model.
Tajaldini M; Samadi F; Khosravi A; Ghasemnejad A; Asadi J
Biomed Pharmacother; 2020 Jan; 121():109594. PubMed ID: 31707344
[TBL] [Abstract][Full Text] [Related]
18. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
19. Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
Yan X; Tang B; Chen B; Shan Y; Yang H;
Elife; 2019 Mar; 8():. PubMed ID: 30860027
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
